Bone marrow transplantation for primary immunodeficiency diseases

Area of Science:

• Immunology
• Hematology
• Genetics

Background:

• Over 120 genes linked to primary immunodeficiency diseases (PID) have been identified, expanding the field of immunology.
• Allogeneic blood or marrow transplantation has been performed on over 1000 children in North America in the past 30 years, with most achieving long-term survival.

Purpose of the Study:

• To review the results, challenges, and advances in hematopoietic stem cell transplantation (HSCT) for severe forms of primary immunodeficiency diseases (PID).
• To highlight novel, less toxic conditioning regimens for PID transplantation.
• To discuss the evolving donor options for HSCT in children with severe PID.

Main Methods:

• Review of existing literature and clinical data on HSCT for primary immunodeficiency diseases (PID).
• Analysis of outcomes associated with different conditioning regimens and donor sources.
• Evaluation of long-term survival rates and challenges in PID transplantation.

Main Results:

• Hematopoietic stem cell transplantation (HSCT) is a viable and often curative option for severe primary immunodeficiency diseases (PID), with a majority of patients achieving long-term survival.
• Advances in less toxic conditioning regimens have improved the safety and efficacy of HSCT for PID.
• While HLA-matched sibling donors are ideal, progress in unrelated HSCT and umbilical cord blood grafts expands treatment possibilities.

Conclusions:

• Hematopoietic stem cell transplantation (HSCT) represents a significant therapeutic advance for children with severe primary immunodeficiency diseases (PID).
• Continued innovation in conditioning protocols and donor selection strategies is crucial for optimizing HSCT outcomes in PID.
• Expanding access to HSCT, including unrelated and cord blood options, offers hope for all children affected by severe PID.